Skip to main content

Table 2 GRADE evidence profile of outcomes, O-SES versus DP-DES

From: Safety and efficacy of ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer drug-eluting stents: a meta-analysis of randomized trials

Outcome

No. of patients (Studies)

Study results (95% CI) and measurements

Absolute effect estimates (per 1000)

Quality

Importance

O-SES

DP-DES

O-SES

DP-DES

Absolute Risk (95% CI)

Myocardial infarction

142/3777 (3.8%)

147/3095 (4.7%)

RR 0.78 (0.62 to 0.98)

37

47

10 fewer (from 1 fewer to 18 fewer)

 High

Critical

Stent thrombosis

50/3767 (1.3%)

63/3095 (2%)

RR 0.75 (0.52 to 1.08)

15

20

5 fewer (from 10 fewer to 2 more)

Moderatea

Important

Cardiac death

50/3777 (1.3%)

50/3095 (1.6%)

RR 0.93 (0.63 to 1.36)

15

16

1 fewer (from 6 fewer to 6 more)

Moderatea

Important

Target vessel revascularization

166/3778 (4.4%)

141/3092 (4.6%)

RR 0.97 (0.78 to 1.21)

45

46

1 fewer (from 10 fewer to 10 more)

 High

Important

Target lesion revascularization

129/3777 (3.4%)

101/3094 (3.3%)

RR 1.1 (0.86 to 1.42)

36

33

3 more (from 5 fewer to 14 more)

 High

Important

  1. CI Confidence interval, RR Risk ratio, O-SES Orsiro biodegradable polymer sirolimus-eluting stent, DP-DES Durable polymer drug-eluting stents;
  2. High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate
  3. aSerious imprecision